Stocks Health care RZLT
NASDAQ · Health careRezolute, Inc. (RZLT)
It posted a net loss of $77.9M. At September 30, 2026 it held $8.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Rezolute, Inc.
- Net worth
- Rezolute, Inc. has a market value (market cap) of $373.6M at the latest share price, and shareholders' equity of $85.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2026 operations used $64.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Rezolute, Inc.'s next report is expected around February 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Rezolute, Inc. does
Rezolute, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RZLT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | n/a | -$77.6M | -$0.75 | n/a |
| 2025 | n/a | -$74.4M | -$0.98 | n/a |
| 2024 | n/a | -$68.5M | -$1.33 | n/a |
| 2023 | n/a | -$51.8M | -$1.01 | -$44.6M |
| 2022 | n/a | -$41.1M | -$2.32 | n/a |
| 2021 | n/a | -$20.9M | -$2.72 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Rezolute, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- November 5, 2026
- October 29, 2026
- October 28, 2026Passive stake (5% or more) SCHEDULE 13G
- October 21, 2026Proxy statement DEF 14A
- October 14, 2026
- October 7, 2026Preliminary proxy statement PRE 14A
- October 5, 2026
- September 24, 2026Annual report10-K · period to June 30, 2026Rezolute reported a net loss of $77.6 million for fiscal year 2026 while advancing clinical studies and maintaining $107.8 million in capital resources.Diluted EPS -$0.75 versus -$0.98.
Insider trades
What the people running Rezolute, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 4 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 21, 2026 | Evans DaronCFO | Gave as a gift | 16,000 | - |
| October 21, 2026 | Evans DaronCFO | Gave as a giftindirect | 4,000 | - |
| October 21, 2026 | Evans DaronCFO | Gave as a giftindirect | 4,000 | - |
| September 2, 2026 | Karnawat Sunil RatilalChief Commercial Officer | Shares withheld for tax | 2,267 | $10.2K |
| July 2, 2026 | Evans DaronCFO | Shares withheld for tax | 3,062 | $15.3K |
| July 2, 2026 | Elam Nevan CCEO, Director | Shares withheld for tax | 8,004 | $39.9K |
| July 2, 2026 | Roberts Brian KennethChief Medical Officer | Shares withheld for tax | 3,062 | $15.3K |
| March 30, 2026 | Evans DaronCFO | Bought | 10,000 | $28.5K |
Who owns RZLT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Healthcare Fund, L.P.13G, passive with 3 related filers | 9.9% | December 18, 2025 |
| Opaleye Management Inc.13G, passive with 2 related filers | 6.58% | May 11, 2026 |
| Dellora Investments LP13G, passive with 2 related filers | 5.9% | August 12, 2026 |
| Jennison Associates LLC13G, passive | 5.5% | October 28, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 144 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Federated Hermes, Inc. | 12,990,659 | 0 |
| RA Capital Management, L.P. | 9,445,039 | +265,039 |
| BlackRock, Inc. | 7,718,291 | +1,404,788 |
| Opaleye Management Inc. | 6,300,000 | 0 |
| Balyasny Asset Management L.P. | 4,662,039 | -386,382 |
| Vanguard Capital Management LLC | 3,835,827 | +313,747 |
| Siren, L.L.C. | 3,328,287 | 0 |
| Jacobs Levy Equity Management, Inc | 2,561,654 | +2,341,247 |
| Jennison Associates LLC | 2,459,308 | -979,573 |
| Geode Capital Management, LLC | 2,170,154 | +205,795 |
| State Street Corp | 1,850,128 | +78,287 |
| D. E. Shaw & Co., Inc. | 1,839,357 | +73,377 |
| Morgan Stanley | 1,618,783 | -1,128,888 |
| Vanguard Portfolio Management LLC | 1,380,746 | -1,601,019 |
| Goldman Sachs Group Inc | 1,316,782 | +714,486 |
| Nuveen, LLC | 1,295,209 | +1,197,523 |
| Kennedy Capital Management LLC | 1,221,678 | -14,420 |
| Blackstone Inc. | 1,082,927 | new |
| Aqr Capital Management LLC | 1,007,962 | +211,266 |
| Affinity Asset Advisors, LLC | 1,000,000 | -547,641 |
Insiders
10 insiders reported holding 1,856,224 shares in total, about $7.2M at the last price.
| Holder | Shares |
|---|---|
| Elam Nevan CCEO, Director | 605,497 |
| Evans DaronCFO | 406,40011,000 held indirectly |
| Roberts Brian KennethChief Medical Officer | 293,851 |
| Kim Young-JinDirector | 170,950 |
| Hogenhuis WladimirDirector | 119,675 |
| Karnawat Sunil RatilalChief Commercial Officer | 69,275 |
| Kreher NerissaDirector | 58,576 |
| Fauchet PhilippeDirector | 55,500 |
| Labrucherie Gil MDirector | 55,500 |
| Harris ErikDirector | 21,000 |
Questions about RZLT
What does Rezolute, Inc. do?
Rezolute, Inc. is a company in the Health care sector, listed on NASDAQ as RZLT. Its shares trade on NASDAQ under the ticker RZLT.
What is Rezolute, Inc.'s net worth?
Rezolute, Inc. has a market value (market cap) of $373.6M at the latest share price, and shareholders' equity of $85.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Rezolute, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $77.9M.
When did Rezolute, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Rezolute, Inc.'s next earnings report?
Rezolute, Inc.'s next report is expected around February 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RZLT with
Follow RZLT
Get an email when Rezolute, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Rezolute, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.